Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PAVmed Inc.PAVM · Entity 7317 | 10% owner | November 24, 2020 | November 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PAVmed Inc.
Report date November 24, 2020 · Filed November 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,060,947 |
Reported balance
After 2020-11-24 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-11-24 · Sale · Disposed 53,036 · Balance 1,060,947 F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,027,744 |
Reported balance
After 2020-11-25 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-11-25 · Sale · Disposed 33,203 · Balance 1,027,744 F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 792,000 |
Reported balance
Holding disclosure · report date 2020-11-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 792,000 F2: Securities of the Issuer held directly by The Boomer Fund, L.P. ("Boomer"). Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the securities of the Issuer held by Boomer. |
| Common StockSEC Table I · non-derivative | Direct | 1,938,297 |
Reported balance
Holding disclosure · report date 2020-11-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,938,297 |
Filing footnotes · ownership attribution and instrument terms
F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation.
F2: Securities of the Issuer held directly by The Boomer Fund, L.P. ("Boomer"). Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the securities of the Issuer held by Boomer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acorda Therapeutics, Inc.
Report date January 30, 2019 · Filed February 01, 2019
Jointly reported with SCOPIA CAPITAL MANAGEMENT LP, Scopia Management, Inc., MINDICH JEREMY
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,750,219 |
Reported balance
After 2019-01-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-01-30 · Sale · Disposed 7,000 · Balance 4,750,219 F1: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles,
F2: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles.
F3: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
ITRON, INC.
Report date May 28, 2019 · Filed May 30, 2019
Jointly reported with SCOPIA CAPITAL MANAGEMENT LP, Scopia Management, Inc., MINDICH JEREMY
Section 16 reporting ended · disclosed 2019-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,925,602 |
Reported balance
After 2019-05-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-05-28 · Sale · Disposed 31,144 · Balance 3,925,602 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on May 20, 2019. F2: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities held in the accounts of the Investment Vehicles reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,202 |
Reported balance
Holding disclosure · report date 2019-05-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,202 F5: Shares of common stock of the Issuer held directly by Matthew Sirovich. |
| Common StockSEC Table I · non-derivative | Direct | 653 |
Reported balance
Holding disclosure · report date 2019-05-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 653 F6: Shares of common stock of the Issuer held directly by Jeremy Mindich. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on May 20, 2019.
F2: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities.
F3: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles.
F4: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities held in the accounts of the Investment Vehicles reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5: Shares of common stock of the Issuer held directly by Matthew Sirovich.
F6: Shares of common stock of the Issuer held directly by Jeremy Mindich.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2019 Filed Jan 28, 2019 16:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 8,600 | $16.03 | $137,851.12 |
DisclosureSEC source: 0000899243-19-002030 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,759,620 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 45,898 | $16.01 | $734,941.73 |
DisclosureSEC source: 0000899243-19-001870 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,768,220 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 51,945 | $16.02 | $831,971.90 |
DisclosureSEC source: 0000899243-19-001870 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,814,118 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 39,358 | $16.24 | $639,327.42 |
DisclosureSEC source: 0000899243-19-001594 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,866,063 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100,000 | $16.86 | $1,685,550.00 |
DisclosureSEC source: 0000899243-19-001594 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,905,421 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 91,650 | $16.94 | $1,552,413.53 |
DisclosureSEC source: 0000899243-19-001353 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,005,421 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 1,700 | $16.60 | $28,223.06 |
DisclosureSEC source: 0000899243-19-001353 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,097,071 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:32 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 40,392 | $17.40 | $702,788.49 |
DisclosureSEC source: 0000899243-19-001225 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,098,771 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 87,491 | $17.29 | $1,512,728.14 |
DisclosureSEC source: 0000899243-19-001035 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,139,163 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 75,000 | $17.05 | $1,278,705.00 |
DisclosureSEC source: 0000899243-19-001035 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,226,654 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 08, 2019 Filed Jan 9, 2019 16:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 59,174 | $16.24 | $960,926.59 |
DisclosureSEC source: 0000899243-19-000841 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,301,654 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 75,000 | $16.56 | $1,241,737.50 |
DisclosureSEC source: 0000899243-19-000841 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,360,828 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 16:08 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 31,591 | $16.61 | $524,713.87 |
DisclosureSEC source: 0000899243-19-000662 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,435,828 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:08 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 23,616 | $15.74 | $371,644.99 |
DisclosureSEC source: 0000899243-19-000662 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,467,419 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 52,891 | $14.99 | $792,751.46 |
DisclosureSEC source: 0000899243-19-000110 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,491,035 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 50,000 | $14.66 | $732,760.00 |
DisclosureSEC source: 0000899243-18-031937 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,543,926 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. F2 · ownership.nature: (Continued From Footnote 1) Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. F3 · ownership.nature: (Continued From Footnote 2) Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 27, 2018 Filed Jan 28, 2019 13:23 UTC | PAVmed Inc. PAVM · Entity 7317 | OtherCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-001732 · doc1.xml · nonDerivative · entry 2 SIROVICH MATTHEW · CIK 0001431208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 792,000 F1 · kind: Securities of PAVMed Inc. (the "Issuer") acquired in settlement of all remaining accrued and unpaid interest outstanding under the Issuer's 15% Senior Secured Note due 2019 in connection with the repayment of such note. F1 · price: Securities of PAVMed Inc. (the "Issuer") acquired in settlement of all remaining accrued and unpaid interest outstanding under the Issuer's 15% Senior Secured Note due 2019 in connection with the repayment of such note. F2 · ownership.nature: Securities of the Issuer held directly by The Boomer Fund, L.P. ("Boomer"). Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the securities of the Issuer held by Boomer. Read SEC document |
| December 27, 2018 Filed Jan 28, 2019 13:23 UTC | PAVmed Inc. PAVM · Entity 7317 | OtherCommon Stock | 272,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-001732 · doc1.xml · nonDerivative · entry 1 SIROVICH MATTHEW · CIK 0001431208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,914 F1 · kind: Securities of PAVMed Inc. (the "Issuer") acquired in settlement of all remaining accrued and unpaid interest outstanding under the Issuer's 15% Senior Secured Note due 2019 in connection with the repayment of such note. F1 · price: Securities of PAVMed Inc. (the "Issuer") acquired in settlement of all remaining accrued and unpaid interest outstanding under the Issuer's 15% Senior Secured Note due 2019 in connection with the repayment of such note. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 50,000 | $14.66 | $732,820.00 |
DisclosureSEC source: 0000899243-18-031937 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,593,926 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. F2 · ownership.nature: (Continued From Footnote 1) Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. F3 · ownership.nature: (Continued From Footnote 2) Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 40,506 | $13.24 | $536,096.91 |
DisclosureSEC source: 0000899243-18-031705 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,643,926 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 2) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 40,000 | $14.03 | $561,368.00 |
DisclosureSEC source: 0000899243-18-031586 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,684,432 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer").Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 1,900 | $16.03 | $30,460.99 |
DisclosureSEC source: 0000899243-18-031586 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,724,432 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer").Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,100 | $15.87 | $49,202.89 |
DisclosureSEC source: 0000899243-18-031586 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,726,332 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer").Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 16:10 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 30,000 | $16.88 | $506,496.00 |
DisclosureSEC source: 0000899243-18-031410 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,729,432 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 16:10 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 50,000 | $16.97 | $848,445.00 |
DisclosureSEC source: 0000899243-18-031410 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,759,432 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:10 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 41,853 | $16.49 | $690,101.56 |
DisclosureSEC source: 0000899243-18-031410 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,809,432 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 17:48 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 28,796 | $16.15 | $464,977.65 |
DisclosureSEC source: 0000899243-18-031240 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,851,285 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, F2 · ownership.nature: (Continued from Footnote 1) as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 17:48 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 33,061 | $16.27 | $537,760.31 |
DisclosureSEC source: 0000899243-18-031240 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,880,081 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, F2 · ownership.nature: (Continued from Footnote 1) as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100,000 | $16.30 | $1,629,790.00 |
DisclosureSEC source: 0000899243-18-030850 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,913,142 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 200,000 | $16.30 | $3,259,500.00 |
DisclosureSEC source: 0000899243-18-030850 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,013,142 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 16:08 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 35,000 | $19.07 | $667,530.50 |
DisclosureSEC source: 0000899243-18-030646 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,213,142 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer").Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 16:08 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 25,210 | $18.77 | $473,070.69 |
DisclosureSEC source: 0000899243-18-030646 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,248,142 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer").Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 16:45 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 40,711 | $18.43 | $750,340.37 |
DisclosureSEC source: 0000899243-18-030389 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,273,352 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 16:45 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,090 | $20.60 | $63,658.94 |
DisclosureSEC source: 0000899243-18-030389 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,314,063 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 03, 2018 Filed Dec 3, 2018 17:03 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100,000 | $20.70 | $2,069,500.00 |
DisclosureSEC source: 0000899243-18-029960 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,317,153 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:03 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 75,000 | $20.48 | $1,536,015.00 |
DisclosureSEC source: 0000899243-18-029960 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,417,153 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 17:03 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 50,000 | $20.20 | $1,009,860.00 |
DisclosureSEC source: 0000899243-18-029960 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,492,153 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 20, 2018 Filed Nov 20, 2018 22:58 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 7,027 | $51.04 | $358,675.65 |
DisclosureSEC source: 0000899243-18-029494 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,086,532 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 22:58 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 11,832 | $53.05 | $627,698.25 |
DisclosureSEC source: 0000899243-18-029494 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,093,559 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 22:54 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 17,137 | $53.49 | $916,629.00 |
DisclosureSEC source: 0000899243-18-029168 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,105,391 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:54 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 11,914 | $52.61 | $626,801.50 |
DisclosureSEC source: 0000899243-18-029168 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,122,528 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:54 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 26,127 | $52.17 | $1,362,961.98 |
DisclosureSEC source: 0000899243-18-029168 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,134,442 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 13, 2018 Filed Nov 13, 2018 22:41 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 17,348 | $53.02 | $919,740.65 |
DisclosureSEC source: 0000899243-18-028746 · doc4.xml · nonDerivative · entry 4 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,160,569 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations and their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 22:41 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 25,870 | $53.37 | $1,380,619.81 |
DisclosureSEC source: 0000899243-18-028746 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,177,917 F4 · balance_after: As of June 30, 2018, Scopia Management ceased to serve as the investment adviser to a certain separately managed account which held 84,721 shares of the Issuer's common stock. On such date, Scopia Management ceased to exercise voting and investment power over such shares and the Reporting Persons ceased to have beneficial ownership of such shares. Due to an oversight, the Form 4 filed on October 3, 2018 did not account for the resulting decrease in Column 5 of Table I, which should have reflected a total of 5,237,263 shares rather than 5,321,984 shares. This Form 4 reflects the decrease in Column 5 of Table I. F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations and their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:41 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 29,323 | $53.91 | $1,580,926.09 |
DisclosureSEC source: 0000899243-18-028746 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,203,787 F4 · balance_after: As of June 30, 2018, Scopia Management ceased to serve as the investment adviser to a certain separately managed account which held 84,721 shares of the Issuer's common stock. On such date, Scopia Management ceased to exercise voting and investment power over such shares and the Reporting Persons ceased to have beneficial ownership of such shares. Due to an oversight, the Form 4 filed on October 3, 2018 did not account for the resulting decrease in Column 5 of Table I, which should have reflected a total of 5,237,263 shares rather than 5,321,984 shares. This Form 4 reflects the decrease in Column 5 of Table I. F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations and their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 22:41 UTC | ITRON, INC. ITRI · Entity 2773 | SaleCommon Stock | 4,153 | $56.07 | $232,841.27 |
DisclosureSEC source: 0000899243-18-028746 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,233,110 F4 · balance_after: As of June 30, 2018, Scopia Management ceased to serve as the investment adviser to a certain separately managed account which held 84,721 shares of the Issuer's common stock. On such date, Scopia Management ceased to exercise voting and investment power over such shares and the Reporting Persons ceased to have beneficial ownership of such shares. Due to an oversight, the Form 4 filed on October 3, 2018 did not account for the resulting decrease in Column 5 of Table I, which should have reflected a total of 5,237,263 shares rather than 5,321,984 shares. This Form 4 reflects the decrease in Column 5 of Table I. F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (Continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations and their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 11, 2018 Filed Oct 12, 2018 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 49,760 | $17.09 | $850,547.68 |
DisclosureSEC source: 0001567619-18-004084 · doc1.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,542,153 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own F2 · ownership.nature: [Continued from footnote 1] the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 93,816 | $16.91 | $1,586,756.92 |
DisclosureSEC source: 0001567619-18-004084 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,591,913 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own F2 · ownership.nature: [Continued from footnote 1] the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 09, 2018 Filed Oct 9, 2018 17:56 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 56,290 | $16.49 | $928,075.75 |
DisclosureSEC source: 0000899243-18-026452 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,685,729 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 17:56 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 60,042 | $17.87 | $1,073,196.71 |
DisclosureSEC source: 0000899243-18-026452 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,742,019 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.